BlinkLab Receives $822,205 R&D Tax Incentive Refund
BlinkLab receives R&D Tax Incentive Refund relating to its U.S. Pilot Study and Australian clinical research initatives

Highlights
- $822,205 R&D Tax Incentive refund received, strengthening BlinkLab’s cash position.
- Refund relates to the U.S. pilot study and clinical research initiatives conducted in Australia and overseas.
BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”) is pleased to announce that it has received $822,205 under the Australian Government’s Research and Development(R&D) Tax Incentive program.
The refund relates to eligible R&D expenditure incurred in connection with BlinkLab’s U.S.pilot study and its clinical research initiatives conducted in Australia, including collaborative research undertaken with the MAGNET study at Monash University1. These Australian and overseas activities support the development, validation and clinical investigation of theCompany’s smartphone-based neurobehavioural assessment technology in autism.
Funds received from the R&D Tax Incentive will be applied to support BlinkLab’s ongoing research and development activities, including continued clinical studies and broader product and regulatory development programs. Receipt of the refund provides additional financial flexibility as the Company prepares to initiate its main FDA study and commence participant enrolment.This announcement has been authorised for release by the Managing Director
This announcement has been authorised for release by the Managing Director.
1) ASX announcement, 13th Nov 2024 - BB1 to Participate in Monash Uni Autism/ADHD MAGNET Project
Invest in BlinkLab
Interested in joining BlinkLab’s growth journey? Explore our Investor Centre.

%20SMALL.jpg)

